Drug targets for Cancer: CD36

Drug Targets for Cancer: CD36 and Cancer

The fact that the identity of the cells that initiate metastasis in most human cancers is unknown hampers the development of antimetastatic therapies. A research described a subpopulation of CD44 bright cells in human oral carcinomas that do not overexpress mesenchymal genes, are slow-cycling, express high levels of the fatty acid receptor CD36 and lipid metabolism genes, and are unique in their ability to initiate metastasis. Palmitic acid or a high-fat diet specifically boosts the metastatic potential of CD36+ metastasis-initiating cells in a CD36-dependent manner. The use of neutralizing antibodies to block CD36 causes almost complete inhibition of metastasis in immunodeficient or immunocompetent orthotopic mouse models of human oral cancer, with no side effects. Clinically, the presence of CD36+ metastasis-initiating cells correlates with a poor prognosis for numerous types of carcinomas, and inhibition of CD36 also impairs metastasis, at least in human melanoma- and breast cancer-derived tumours.

Drug Targets for Cancer: CD36 related Products

Drug targets for cancer: CD36 research reagents

Other vital drug targets for cancer likeCD36:

Drug Targets for Cancer: CD36 Related Reference

Pascual G, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36[J]. Nature, 2017, 541(7635): 41-45.

Drug Targets for Cancer: CD36 Related Information

Drug Targets for Cancer